You just read:

Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis

News provided by

Eli Lilly and Company

Aug 23, 2019, 14:55 ET